Pricing Log in Create free account
Friday 6 November 2026 Export VIR’s income statement to Excel — free account

Vir Biotechnology, Inc.

VIR Healthcare Biotechnology

Revenue
−178.3%
EPS
+51.4%
Free cash flow
+200.5%

Quarter to September 2026, against a year earlier

12.19 1.17 +10.62%
Market cap
$1.9B
P/E
0.0×
Fwd P/E
−6.5×
Dividend yield
—
F-score
4/9
Altman Z
−0.57
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 2.75
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — 1 13 2 2 1 2 — — — — 1
Insider Ownership 20.80%

Capital & Financial Ratios $m

Size
Market Cap 1,860.00
Revenue ttm 302.80
Net income ttm (184.79)
Free cash flow ttm (141.93)
Net debt Q (460.29)
Valuation
P/E 0.00
Forward P/E (6.52) (negative: loss-making)
Price / sales 6.81
Forward P/S Powerpack
Price / FCF 0.00
Price / book 2.30
Financial health
Current ratio Q 6.30 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q —
Growth
Revenue growth Q −178.33% (below 0%: shrinking)
Operating income growth Q +39.66% (above 0%: growing)
EPS, this year +58.85% (at or above 15%: strong)
EPS, next year A −77.01% (below 0%: weak)
Revenue, next year A +249.20% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +14.00%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 5.3×, against a ten-year median of 2.9×; over the ten years it ranged from −20.4× in 2019 to 330× in 2020.
P/S against its own 10 years 26.38%
10-year low 10-year high
P/B against its own 10 years 70.63%
10-year low 10-year high
EV/Sales against its own 10 years 50.32%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 1,536 995 469 460
Receivables — — — —
Inventory — — — —
Other — — — —
1,588 1,042 514 508
2023 2024 2025 Q'26
Payables 6 5 10 11
ST’ Debt — — — —
Other — 16 — —
175 120 93 81

Compound Annual Growth %

10y 5y 3y
Sales — (2.14%) (65.12%)
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 1.32% (28.32%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −0.80 Actual −0.57

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 −0.42 −0.31 Beat by 0.11
Q1 FY26 −0.01 −0.85 Miss by 0.84
Q2 FY26 0.83 0.47 Miss by 0.36
Q3 FY26 −0.80 −0.57 Beat by 0.23
Q4 FY26 −0.76 — Reports 22 February 2027

EPS $

Mar Jun Sep Dec Year
’26 (0.85) 0.47 (0.57) — —
’25 (0.88) (0.80) (1.17) (0.31) (3.16)
’24 (0.48) (1.02) (1.56) (0.76) (3.83)
’23 (1.06) (1.45) (1.22) (0.86) (4.59)
’22 3.85 (0.58) 1.30 (0.76) 3.83
’21 (1.32) 0.46 0.82 3.92 3.96
’20 (0.71) (0.27) (0.67) (0.83) (2.51)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 0 239 — — —
’25 3 1 0 64 69
’24 56 3 2 12 74
’23 63 4 3 17 86
’22 1,232 (41) 375 49 1,616
’21 2 177 104 813 1,095
’20 6 67 2 2 76
Fiscal quarters ending in the months shown.
value withheld pending a data check

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (132) 123 (106) — —
’25 (78) (120) (168) (26) (392)
’24 (109) (78) (171) (88) (446)
’23 (126) (389) (156) (108) (779)
’22 550 960 118 35 1,663
’21 (90) 140 (106) 8 (48)
’20 (48) (11) (50) (82) (191)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (133) 123 (106) — —
’25 (79) (123) (168) (26) (396)
’24 (111) (78) (174) (87) (450)
’23 (133) (399) (160) (109) (800)
’22 534 940 99 23 1,595
’21 (90) 138 (112) (5) (69)
’20 (50) (12) (51) (84) (197)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — 3 11 8 76 1,095 1,616 86 74 69 303 +49.8% 239 76 107 +16.1%
Gross margin, % — 100.00 100.00 100.00 100.00 93.99 90.94 96.79 98.86 99.96 99.99 0.0 pt
EBT — (81) (116) (175) (299) 550 754 (628) (523) (438) (185) +23.5%
EBT margin, % — (2,982.87) (1,090.78) (2,157.08) (391.02) 50.19 46.68 (728.93) (704.95) (638.56) (61.00) +2,344.3 pt
Net income — (70) (116) (175) (299) 529 516 (615) (522) (438) (185) +25.8%
Per share, $
Per share, $ Revenue — 1.26 1.39 0.27 0.64 8.43 12.18 0.64 0.54 0.49 1.79 (11.0%)
Earnings — (32.46) (15.12) (5.76) (2.51) 4.07 3.89 (4.59) (3.83) (3.16) (1.25) (25.3%)
Cash flow — (30.85) (12.27) (4.27) (1.60) (0.37) 12.54 (5.81) (3.28) (2.83) (0.83) (25.8%)
Capex — (1.27) (1.07) (0.29) (0.05) (0.17) (0.51) (0.16) (0.03) (0.03) (0.01) (36.6%)
Free cash flow — (32.12) (13.34) (4.57) (1.66) (0.53) 12.03 (5.97) (3.30) (2.86) (0.84) (26.1%)
Book value — 0.00 (23.37) 13.97 6.02 11.02 15.67 11.86 8.44 5.52 5.29 n/m
Shares, m — 2 8 30 119 130 133 134 136 139 156 +68.3%
Valuation, ×
Valuation, × P/E — 0.00 0.00 0.00 0.00 10.42 6.37 0.00 0.00 0.00 0.00 1.9
P/S — 0.00 14.73 47.19 41.79 4.96 2.05 16.36 13.48 12.18 6.81 17.0
P/B — 0.00 0.00 0.90 4.45 3.80 1.59 0.89 0.87 1.09 2.30 1.5
EV/Sales — 0.00 (18.19) (0.97) 32.03 4.31 0.55 (1.46) 0.07 5.34 5.29 2.4
EV/FCF — 0.00 1.39 0.06 (12.40) (68.03) 0.56 0.16 (0.01) (0.92) (11.30) (8.8)
Cash, $m
Cash, $m Operating cash flow — (66) (94) (130) (191) (48) 1,663 (779) (446) (392) (141) +24.8%
Capex — (3) (8) (9) (6) (22) (68) (22) (4) (5) (1) +6.6%
Free cash flow — (69) (102) (139) (197) (69) 1,595 (800) (450) (396) (142) +24.4%
Balance, $m
Balance, $m Working capital — 180 78 344 673 1,222 2,008 1,413 923 421 428 +11.2%
Net debt — (188) (109) (390) (745) (717) (2,415) (1,536) (995) (469) (460) +12.1%
Shareholders’ equity — — (179) 424 717 1,432 2,078 1,590 1,150 765 896 n/m
Returns, %
Returns, % ROA — (31.46) (120.97) (49.65) (41.75) 36.80 21.69 (26.06) (31.46) (36.47) (17.34) (5.0) pt
ROIC — 0.00 0.00 (324.07) 0.00 36.77 0.00 (783.90) (235.77) (101.09) (30.32) (101.1) pt
ROE — 56.33 93.39 (142.74) (52.36) 49.20 29.39 (33.53) (38.09) (45.73) (21.84) (102.1) pt
People
People Employees — — — 229 327 444 576 587 408 367 — +8.2%
Revenue/emp, $m — 0.00 0.00 0.04 0.23 2.47 2.81 0.15 0.18 0.19 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 6 Nov 2026

Vir Biotechnology, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
TRAX First Tracks Biotherapeutics, Inc. $1.9B — (loss-making) — — n/m +55.91% (above 0%: growing) — 0.00% Compare
REPL Replimune Group, Inc. $1.9B — (loss-making) — — n/m +42.22% (above 0%: growing) 0.00% 0.00% Compare
HRMY Harmony Biosciences Holdings, Inc. $1.9B 10.7× 9.9× +12.30% (above 0%: growing) −6.24% (below 0%: shrinking) −29.42% (below 0%: shrinking) 70.00% 20.15% Compare
VIR Vir Biotechnology, Inc. $1.9B — (loss-making) — (loss-making) −178.33% (below 0%: shrinking) n/m +200.47% (above 0%: growing) 100.00% 55,669.15%
SRPT Sarepta Therapeutics, Inc. $1.9B — (loss-making) 6.3× −4.51% (below 0%: shrinking) n/m +231.84% (above 0%: growing) 0.00% (2.37%) Compare
MESO Mesoblast Limited $1.8B — (loss-making) — −13.41% (below 0%: shrinking) n/m −89.23% (below 0%: shrinking) (353.35%) (909.40%) Compare
TRVI Trevi Therapeutics, Inc. $1.8B — (loss-making) — — n/m −73.77% (below 0%: shrinking) 0.00% 0.00% Compare
MAZE Maze Therapeutics, Inc. $1.8B — (loss-making) — — n/m +50.21% (above 0%: growing) 100.00% 0.00% Compare
MRVI Maravai LifeSciences Holdings, Inc. $1.8B — (loss-making) — (loss-making) +10.14% (above 0%: growing) n/m +123.88% (above 0%: growing) 35.31% (44.97%) Compare
Median of peers $1.8B — — +2.82% — +46.22% 0.00% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 16 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 7.83m 3.10m 22.52

Ownership

Directors and executive officers, together 2.90%
BlackRock, Inc. 9.20%
SVF Endurance (Cayman) Ltd. 8.10%
Entities affiliated with ARCH Venture Partners, L.P. 8.00%
Glaxo Group Limited 5.30%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Vir Biotechnology, Inc. (VIR) Latest News

5 Nov

Impact 4 · · The Motley Fool transcript
Impact 3 · · Business Wire
Impact 3 · · Moby transcript
Impact 3 · · MarketBeat transcript
Impact 3 · · GuruFocus.com

4 Nov

Impact 3 · · Business Wire

28 Oct

Impact 4 · · Business Wire

26 Oct

Impact 4 · · Simply Wall St.

21 Oct

Impact 3 · · Business Wire

17 Oct

Impact 3 · · Simply Wall St.

15 Oct

Impact 4 · · Zacks
Impact 4 · · pharmaceutical-technology.com

14 Oct

Impact 4 · · MT Newswires
Impact 4 · · Business Wire
Impact 3 · · Simply Wall St.

8 Oct

Impact 4 · · Business Wire
Impact 3 · · Simply Wall St.

7 Oct

Impact 4 · · Business Wire

5 Oct

Impact 3 · · Business Wire

1 Oct

Impact 3 · · Business Wire

12 Aug

Impact 3 · · The Motley Fool transcript

6 Aug

Impact 4 ·
Impact 3 · · Moby transcript
Impact 3 · · MarketBeat transcript

5 Aug

Impact 3 ·
Impact 3 ·

2 Jul

Impact 3 ·
Impact 3 ·

24 May

Impact 4 · · Simply Wall St.

18 May

Impact 3 · · Business Wire
stockrow.com/VIR · Data as of Nov 6, 2026 · For information only; not investment advice. · © 2026 stockrow.com